Published in Cancer Res on December 15, 1996
Telomerase activity, cell proliferation, and cancer. Proc Natl Acad Sci U S A (1998) 2.40
Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol (2009) 1.88
A non-isotopic method for the detection of telomerase activity in tumour tissues: TRAP-silver staining assay. Mol Pathol (1998) 1.44
Cyclin D1 overexpression and p53 inactivation immortalize primary oral keratinocytes by a telomerase-independent mechanism. J Clin Invest (2001) 1.14
Genetic heterogeneity in saliva from patients with oral squamous carcinomas: implications in molecular diagnosis and screening. J Mol Diagn (2001) 1.07
Early glandular neoplasia of the lung. Respir Res (2000) 0.98
Role of CD44 as a marker of cancer stem cells in head and neck cancer. Biologics (2012) 0.88
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review. Int J Nanomedicine (2014) 0.84
TCAB1: a potential target for diagnosis and therapy of head and neck carcinomas. Mol Cancer (2014) 0.84
Salivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma. Head Neck (2011) 0.81
Telomerase activity detected in oral lichen planus by RNA in situ hybridisation: not a marker for malignant transformation. J Clin Pathol (2002) 0.77
Telomerase activity is frequently found in metaplastic and malignant human nasopharyngeal tissues. Br J Cancer (2000) 0.77
Quantification of telomerase activity in normal oral mucosal tissue and oral squamous cell carcinoma. Indian J Med Paediatr Oncol (2016) 0.75
Recent advances in biomarkers and potential targeted therapies in head and neck squamous cell carcinoma. ISRN Surg (2012) 0.75
Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications. Cancer Metastasis Rev (2016) 0.75
Telomerase detection in the diagnosis and prognosis of cancer. Cytotechnology (2004) 0.75
p53 mutations in human cancers. Science (1991) 31.96
Participation of p53 protein in the cellular response to DNA damage. Cancer Res (1991) 16.00
Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst (2000) 14.43
5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med (1995) 9.10
Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res (1995) 7.42
Head and neck cancer. N Engl J Med (2001) 7.32
Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 5.10
Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res (1996) 4.89
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res (1997) 4.73
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res (1998) 4.33
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab (2013) 3.88
Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet (1995) 3.76
DPC4 gene in various tumor types. Cancer Res (1996) 3.74
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab (2007) 3.44
Mandatory second opinion surgical pathology at a large referral hospital. Cancer (1999) 3.40
Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med (1995) 3.31
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18
Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res (1997) 3.17
Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res (1999) 3.15
Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res (2000) 2.99
p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res (1993) 2.99
Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med (1996) 2.95
Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst (2001) 2.93
Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res (2000) 2.79
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia (2013) 2.67
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab (2013) 2.63
Role of the p16 tumor suppressor gene in cancer. J Clin Oncol (1998) 2.51
p16(MTS-1/CDKN2/INK4a) in cancer progression. Exp Cell Res (2001) 2.34
Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (1999) 2.34
Brief report: molecular biology and the early detection of carcinoma of the bladder--the case of Hubert H. Humphrey. N Engl J Med (1994) 2.22
A new human p53 homologue. Nat Med (1998) 2.21
Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res (2001) 2.18
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
Identification of a mononucleotide repeat as a major target for mitochondrial DNA alterations in human tumors. Cancer Res (2001) 2.10
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract (2013) 2.09
Rapid p53 sequence analysis in primary lung cancer using an oligonucleotide probe array. Proc Natl Acad Sci U S A (1999) 2.08
The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res (1993) 2.05
Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst (2001) 2.04
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab (2014) 1.99
Detection of mitochondrial DNA mutations in primary breast cancer and fine-needle aspirates. Cancer Res (2001) 1.98
Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res (2000) 1.91
Microsatellite alterations as clonal markers for the detection of human cancer. Proc Natl Acad Sci U S A (1994) 1.81
Multiple head and neck tumors: evidence for a common clonal origin. Cancer Res (1996) 1.80
Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst (1998) 1.78
A novel p16INK4A transcript. Cancer Res (1995) 1.74
Analysis of PTEN/MMAC1 alterations in aerodigestive tract tumors. Cancer Res (1998) 1.71
Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin Cancer Res (2001) 1.71
Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res (1994) 1.68
Serial analysis of gene expression in non-small cell lung cancer. Cancer Res (1998) 1.67
Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene (2001) 1.66
Genetic divergence in the clonal evolution of breast cancer. Cancer Res (1996) 1.63
Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res (2001) 1.63
Infrequent p53 gene mutations in medulloblastomas. Cancer Res (1991) 1.62
Microsatellite instability at AAAG repeat sequences in respiratory tract cancers. Int J Cancer (2001) 1.62
Diagnosis of renal cancer by molecular urinalysis. J Natl Cancer Inst (1999) 1.60
Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope (1999) 1.55
Molecular characteristics of non-small cell lung cancer. Proc Natl Acad Sci U S A (2001) 1.53
Esthesioneuroblastoma: the Johns Hopkins experience. Head Neck (2000) 1.51
Allelotype of head and neck squamous cell carcinoma. Cancer Res (1994) 1.47
Detection and quantitation of human papillomavirus (HPV) DNA in the sera of patients with HPV-associated head and neck squamous cell carcinoma. Clin Cancer Res (2000) 1.46
Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst (2000) 1.45
Molecular detection of primary bladder cancer by microsatellite analysis. Science (1996) 1.44
Frequent microsatellite instability in primary small cell lung cancer. Cancer Res (1994) 1.44
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer (1997) 1.42
Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res (1994) 1.40
Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res (2001) 1.39
Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle's cell, and poorly differentiated human thyroid carcinoma. Cancer Res (1998) 1.39
Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene (1998) 1.36
PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol (1999) 1.36
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes Metab (2014) 1.36
Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. Nat Med (1996) 1.35
Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res (2001) 1.34